Eli Lil­ly throws down the gaunt­let in obe­si­ty race, chal­leng­ing No­vo Nordisk with new PhI­II read­out

No­vo Nordisk made waves ear­ly last year af­ter show­ing that its block­buster di­a­betes drug was al­so high­ly ef­fec­tive at treat­ing non-di­a­bet­ic adults with obe­si­ty. But now Eli Lil­ly has fired a warn­ing shot across No­vo’s bow, putting forth its own set of obe­si­ty da­ta for its ex­per­i­men­tal drug tirzepatide.

In a Phase III study com­par­ing three dose lev­els of the drug to place­bo, tirzepatide re­duced pa­tients’ weights by an av­er­age of 16%, 21.4% and 22.5% at the re­spec­tive dos­es, com­pared to just 2.4% on place­bo. Lil­ly did not re­port p-val­ues for the study, but in­stead pro­duced fig­ures as “ef­fi­ca­cy es­ti­mands,” which it said rep­re­sent­ed the ef­fi­ca­cy pri­or to dis­con­tin­u­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.